 randomized double-blind study gallium nitrate etidronate acute control cancer-related hypercalcemia Hypercalcemia major source morbidity mortality patients cancer Gallium nitrate bisphosphonate etidronate new agents available treatment disorder therapeutic effectiveness double-blind multicenter study gallium nitrate etidronate acute control cancer-related hypercalcemia Gallium nitrate continuous intravenous IV infusion dose Etidronate IV infusion dose mg/kg drugs consecutive days Eligible patients persistent moderate-to-severe hypercalcemia total serum calcium serum albumin equal mg/dL days hospitalization IV hydration patients patients gallium nitrate normocalcemia patients etidronate etidronate amounts IV fluids hypocalcemic drug treatment poststudy period patients gallium nitrate Kaplan-Meier analysis median duration normocalcemia patients gallium nitrate days days proportion patients gallium nitrate asymptomatic hypophosphatemia patients etidronate gallium nitrate effective superior acute control moderate-to-severe cancer-related hypercalcemia